shutterstock-178371752
Rawpixel / Shutterstock.com
25 March 2015Biotech

Case review: Biogen v Medeva, 20 years on

It may be hard to imagine Napoleon and the Duke of Wellington sitting down to reminisce after the Battle of Waterloo, and it’s perhaps just as hard to imagine warring legal parties doing so after a long and hard-fought battle. But that is what happened in February when the parties involved in the landmark patent case Biogen v Medeva met to reminisce about their involvement in the case before an invited audience.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Biotech
15 September 2026   Grail is facing a patent infringement lawsuit over its Galleri cancer detection test, as Clinical Genomics seeks to enforce its intellectual property while no longer being commercially operational.
Biotech
3 September 2026   Turnaround for 10x after Federal Circuit setback as Delaware jury finds Qiagen-owned Parse infringed three patents covering single-cell sequencing technology.
Biotech
1 September 2026   Judges dismissed an appeal from MSN Laboratories, which was hoping to show that several patents covering Cabometyx were invalid and would not be infringed by its generic product.